Heghine Khachatryan: Cancer-Associated ATE – An Underrecognized Challenge in Modern Oncology
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared a post on LinkedIn:
“Cancer-Associated Arterial Thromboembolism (ATE): An Underrecognized Challenge in Modern Oncology
Highlights from ISTH 2026 | Paris – July 11, 2026
One of the most thought-provoking sessions on the opening day of ISTH 2026 focused on a topic that has received far less attention than cancer-associated venous thromboembolism: arterial thromboembolism (ATE).
Ang Li, on behalf of the Cosmos Hematology Research Collaborative (Baylor College of Medicine), presented one of the largest real-world analyses evaluating arterial thrombosis after cancer diagnosis using the nationwide Epic Cosmos electronic health record database, including 1.74 million patients with newly diagnosed cancer from 190 U.S. institutions.
The study addressed three clinically important questions:
- What is the cumulative incidence of ATE following cancer diagnosis?
- Which patient-, cancer-, and treatment-related factors increase risk?
- How does ATE influence overall mortality?
Several messages stood out.
Although venous thromboembolism has long been the primary focus of cancer-associated thrombosis research, arterial events – including myocardial infarction and ischemic stroke – represent a substantial yet under-recognized contributor to morbidity and mortality.
Previous studies have suggested that the risk of arterial thromboembolism is several-fold higher in patients with cancer than in the general population, but contemporary nationwide data have been limited.
The strength of this analysis lies in its scale and methodology. By leveraging structured, de-identified EHR data from over 266 healthcare sites, investigators created a representative national cohort, enabling robust evaluation of cancer-specific cardiovascular complications across diverse populations.
Beyond epidemiology, the presentation emphasized a critical clinical message: arterial thrombotic events should become an integral component of cardio-oncology and cancer-associated thrombosis risk assessment.
Early identification of patients at highest risk may improve surveillance strategies, multidisciplinary management, and ultimately patient outcomes.
As our understanding of cancer-associated thrombosis continues to evolve, the conversation is clearly expanding beyond venous disease. Future research should focus on developing validated prediction models for arterial thromboembolism and identifying preventive strategies that appropriately balance thrombotic and bleeding risks.
This session highlighted an important shift in the field: arterial thrombosis is no longer a rare complication—it is an essential part of comprehensive cancer care that deserves greater clinical attention.”
Stay Updated with the Latest ISTH 2026 Updates on Hemostasis Today.
-
Aug 9, 2026, 09:29Michael Wilkinson: How Lp(a) Shapes Coronary Plaque and Cardiovascular Risk
-
Aug 9, 2026, 09:16Preparing for Gene Therapy Starts with Understanding Immunity – WFH
-
Aug 9, 2026, 08:46Christina Pohlman: Uncovering the Autoantibodies Behind APS
-
Aug 9, 2026, 08:39Alejandro González Veliz: The Future of Cardiogenic Shock Lies in Precision Medicine
-
Aug 9, 2026, 08:29Heba Youssef: Off-Label Doesn’t Mean Off-Guidelines
-
Aug 9, 2026, 08:18Fawaz AlOtaibi: Why Experts Are Challenging the New Stroke Guideline
-
Aug 9, 2026, 08:08Jason Carney: Addressing the National Blood Shortage Through AI-Driven Patient Blood Management
-
Aug 9, 2026, 07:54Hamdy Alkady: FDA Approves the First Oral PCSK9 Inhibitor
-
Aug 9, 2026, 07:51Mostafa Hammam: Antibody Panels in Blood Bank Feeling Like a Chaotic Puzzle? Here is How to Master the Grid